SCHEMBL1740936

SCHEMBL1740936

CN(C=S)c1ccccc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 5/20 0.42
KMT2A Q03164 5/20 0.42
HTT P42858 1/20 0.42
FAAH O00519 1/20 0.41
PHGDH O43175 1/20 0.41
MGLL Q99685 1/20 0.41
CA12 O43570 1/20 0.41
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41
CA9 Q16790 1/20 0.41
L3MBTL1 Q9Y468 2/20 0.40
LMNA P02545 1/20 0.40
ALDH1A1 P00352 7/20 0.39
MAPT P10636 4/20 0.39
ALOX15 P16050 3/20 0.39
HPGD P15428 3/20 0.39
HSD17B10 Q99714 2/20 0.39
GAA P10253 2/20 0.39
GLA P06280 1/20 0.39
POLB P06746 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11824897 0.77 ALDH1A1 (0.52) CA1CA2CA9LMNAALDH1A1
SCHEMBL7053933 0.76 MEN1 (0.44) MEN1KMT2AHTTFAAHPHGDH
SCHEMBL3242845 0.75 MEN1 (0.39) MEN1KMT2AHTTFAAHPHGDH
SCHEMBL2584789 0.75 ACHE (0.44) MEN1KMT2ALMNAALDH1A1MAPT
SCHEMBL3293248 0.74 MEN1 (0.42) MEN1KMT2AHTTFAAHPHGDH
SCHEMBL5526432 0.74 MEN1 (0.48) MEN1KMT2AHTTFAAHPHGDH
SCHEMBL1332400 0.74 MEN1 (0.48) MEN1KMT2AHTTFAAHPHGDH
SCHEMBL16935739 0.74 KMT2A (0.42) MEN1KMT2AHTTFAAHPHGDH
SCHEMBL29959966 0.74 MEN1 (0.48) MEN1KMT2AHTTFAAHPHGDH
SCHEMBL66606 0.74 MEN1 (0.48) MEN1KMT2AHTTFAAHPHGDH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8871944-B2 Thiazole derivative and process for producing same GIFU UNIVERSITY (JP) 2014-10-28 US claimed
EP-2388253-B1 THIAZOLE DERIVATIVE AND PROCESS FOR PRODUCING SAME UNIV GIFU (JP) 2015-02-11 EP disclosed
EP-2388253-B1 THIAZOLE DERIVATIVE AND PROCESS FOR PRODUCING SAME UNIV GIFU (JP) 2015-02-11 EP disclosed
US-8871944-B2 Thiazole derivative and process for producing same GIFU UNIVERSITY (JP) 2014-10-28 US disclosed
US-20140031376-A1 IMINOPROPENE COMPOUND AND USE THEREOF SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2014-01-30 US disclosed
US-8618329-B2 Iminopropene compound and use thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2013-12-31 US disclosed
US-20130150392-A1 IMINOPROPENE COMPOUND AND USE THEREOF SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2013-06-13 US disclosed
EP-2601837-A1 PEST CONTROL COMPOSITION Sumitomo Chemical Company, Limited (JP) 2013-06-12 EP disclosed
US-8410316-B2 Iminopropene compound and use thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2013-04-02 US disclosed
US-20110319616-A1 THIAZOLE DERIVATIVE AND PROCESS FOR PRODUCING SAME GIFU UNIVERSITY (JP) 2011-12-29 US disclosed
EP-1167366-B1 AMINE DERIVATIVES DAIICHI SANKYO CO LTD (JP) 2010-05-05 EP disclosed
EP-1957459-A2 IMINOPROPENE COMPOUND AND USE THEREOF Sumitomo Chemical Company, Limited (JP) 2008-08-20 EP disclosed
WO-2007063702-A2 IMINOPROPENE COMPOUND AND USE THEREOF SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2007-06-07 WO disclosed
US-6562849-B1 Amine compound or pharmacologically acceptable salt thereof. These compounds are useful in the treatment and/or prophylaxis of diseases such as diabetes, hyperlipemia, arteriosclerosis, cancer, etc. SANKYO COMPANY, LIMITED (JP) 2003-05-13 US disclosed
US-20030078426-A1 Amine derivative compounds SANKYO COMPANY, LIMITED (JP) 2003-04-24 US disclosed
EP-1167366-A1 AMINE DERIVATIVES Sankyo Company, Limited (JP) 2002-01-02 EP disclosed
US-4933355-A ALDOSE REDUCTASE INHIBITORS SANKYO COMPANY LIMITED (JP) 1990-06-12 US disclosed
EP-0337819-A1 Thiazole derivatives, their preparation and their use in the treatment of diabetes complications Sankyo Company Limited (JP) 1989-10-18 EP disclosed
US-4008228-A Process for preparing 3-methyl-3-cephem antibiotics ELI LILLY AND COMPANY (US) 1977-02-15 US disclosed
US-3979369-A DIENE POLYMER MONSANTO COMPANY (US) 1976-09-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140031376-A1 IMINOPROPENE COMPOUND AND USE THEREOF IMPA1, INPP5A, CTRL MEN1 55/4885KMT2A 1674/4885HTT 1657/4885
US-20130150392-A1 IMINOPROPENE COMPOUND AND USE THEREOF IMPA1, INPP5A, CTRL MEN1 55/4885KMT2A 1674/4885HTT 1657/4885
US-20030078426-A1 Amine derivative compounds H1-10, APOB, PRMT1 MEN1 300/4885KMT2A 85/4885HTT 3024/4885
US-20110319616-A1 THIAZOLE DERIVATIVE AND PROCESS FOR PRODUCING SAME TST, TALDO1, TBCD MEN1 2301/4885KMT2A 3296/4885HTT 1888/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.